Abeona Therapeutics Inc. (ABEO) Trading 5.1% Higher
Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) traded up 5.1% during trading on Monday . The stock traded as high as $5.14 and last traded at $5.11, with a volume of 248,248 shares changing hands. The stock had previously closed at $4.86.
Several analysts recently commented on the company. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 12th. Cantor Fitzgerald assumed coverage on Abeona Therapeutics in a research report on Wednesday, September 7th. They issued a “buy” rating and a $21.00 target price on the stock. FBR & Co restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Friday, August 26th. Rodman & Renshaw restated a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a research report on Sunday, August 21st. Finally, Maxim Group set a $6.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Abeona Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $12.40.
The stock’s market cap is $171.41 million. The stock’s 50-day moving average is $4.20 and its 200 day moving average is $3.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/abeona-therapeutics-inc-abeo-trading-5-1-higher.html
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, equities analysts predict that Abeona Therapeutics Inc. will post ($0.73) earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. Sabby Management LLC increased its stake in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares during the last quarter. Geode Capital Management LLC increased its stake in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares during the last quarter. Royce & Associates LP increased its stake in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares during the last quarter. Finally, BlackRock Fund Advisors increased its stake in Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares during the last quarter. 19.95% of the stock is currently owned by institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.